Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07494773 · ClinicalTrials.gov registry record · Early Phase 1
Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection
A Early Phase 1 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07494773: Clinical Trial Early Phase 1 study, sponsored by University of Oklahoma.
NCT07494773 is a Early Phase 1 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07494773, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Burn wound infections remain a major source of morbidity in patients with thermal injuries and contribute to delayed healing, graft loss, and prolonged hospitalization. The emergence of antimicrobial-resistant organisms further complicates management and highlights the need for non-antibiotic antimicrobial strategies. Photodynamic therapy (PDT) is an antimicrobial approach that combines a photosensitizing agent with visible light to generate reactive oxygen species capable of killing bacteria. This randomized clinical trial will evaluate the safety and preliminary efficacy of methylene blue-mediated photodynamic therapy for the treatment of burn wound bacterial contamination. Participants receiving standard burn care will be randomized to receive either methylene blue-photodynamic therapy with blue light illumination or light therapy alone during routine dressing changes. Treatments will occur during two consecutive dressing changes. The primary objective is to determine whether methylene blue photodynamic therapy reduces bacterial burden in burn wounds compared with light therapy alone. Secondary outcomes include safety, tolerability, and effects on wound healing.
Primary Outcome
Burn wound healing will be quantified using standardized digital photography and planimetric image analysis to measure wound surface area over time. Images will be obtained using a calibrated imaging system with a measurement scale included in each image. Wound area measurements will be analyzed longitudinally to assess changes in wound size over the study period.
Interventions
- DRUG Methylene Blue
- DEVICE Blue Light Illumination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-05-31 |
| Phase | Early Phase 1 |
What is known before NCT07494773 opens enrollment
NCT07494773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Methylene Blue is the first listed.
NCT07494773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07494773 about?
NCT07494773 is a clinical study titled "Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection". Burn wound infections remain a major source of morbidity in patients with thermal injuries and contribute to delayed healing, graft loss, and prolonged hospitalization. The emergence of antimicrobial-resistant organisms further complicates management and highlights the need for non-antibiotic antimi...
What is the current status of trial NCT07494773?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-06. Estimated completion is 2028-05-31.
What interventions are being tested in trial NCT07494773?
The interventions under investigation include: Methylene Blue (DRUG), Blue Light Illumination (DEVICE).
Who is sponsoring clinical trial NCT07494773?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07494773's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,467 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia